

Cytomegalovirus (CMV) IgG ELISA Kit (Human) (OKNX00121) Instructions for use

For the qualitative detection of Anti-Cytomegalovirus IgG in human serum.

This product is intended for research use only.

Lot to lot kit variations can occur. Use the kit manual which has been provided along with the kit packaging.



Table of Contents

1.	Background	2
2.	Assay Summary	3
3.	Storage and Stability	3
4.	Kit Components	3
5.	Precautions	4
6.	Required Materials Not Supplied	4
7.	Technical Application Tips	4
8.	Reagent Preparation	5
9.	Sample Preparation	6
10.	Assay Procedure	7
11.	Calculation of Results	8
12	Typical Expected Data	9
13	Technical Resources	10



1. Background

Principle

Aviva Systems Biology Cytomegalovirus (CMV) IgG ELISA Kit (Human) (OKNX00121) is based on standard reverse capture sandwich enzyme-linked immuno-sorbent assay technology. Cytomegalovirus antigen has been pre-coated and blocked in a 96-wellplate (12 x 8 Well Strips). Standards or test samples are added to the wells, incubated and washed. An HRP conjugated detector antibody specific for Human IgG is added, incubated and followed by washing. An enzymatic reaction is produced through the addition of substrate which is catalyzed by HRP generating a blue color product that changes to yellow after adding acidic stop solution. The density of yellow coloration is read by absorbance at 450 nm and is qualitatively proportional to the amount of sample anti-Cytomegalovirus IgG captured the in well.

Background

Cytomegalovirus (CMV) is a member of the herpesvirus group (Betasubfamily, DNA virus of 150-200 nm). These viruses share a characteristic ability to remain dormant within the body over a long period. Initial CMV infection, which may have few symptoms, is always followed by a prolonged, inapparent infection during which the virus resides in cells without causing detectable damage or clinical illness. Severe impairmant of the body's immune system by medication or disease consistently reactivates the virus from the latent or dormant state. CMV is found universally throughout all geographic locations and socioeconomic groups, and infects between 50% and 85% of adults. CMV infection is more widespread in developing countries and in areas of lower socioeconomic conditions.

For the vast majority of people, CMV infection is not a serious problem, but it is to certain high-risk groups:

the unborn baby during pregnancy

people who work with children

immunocompromised persons, such as organ transplant recipients and persons infected with HIV

Species	Disease	Symptoms	Mechanism of Infection
Cytomegalovirus	Cytomegaly (Cytomegalic inclusion disease or Inclusion body disease)	Mononucleosis-like syndrome, mild hepatitis Complications in infants resulting from congenital CMV disease: hearing and mental or coordination problems	Transmission from person to person: Infection requires close, intimate contact with a person excreting the virus in their saliva, urine, or other bodily fluids. CMV can be sexually transmitted and can also be transmitted via breast milk, transplanted organs, and rarely from blood transfusions


The presence of virus resp. infection may be identified by Microscopy

PCR

Serology: CBR, Detection of antibodies by ELISA



2. Assay Summary



3. Storage and Stability

• Upon receipt store kit at 4°C for 6 months.

4. Kit Components

•The following reagents are the provided contents of the kit.

Description	Quantity	Storage Conditions		
Cytomegalovirus IgG Microplate	96 Wells (12 x 8 Well strips)			
Sample Diluent	White Cap	1 x 100 mL		
Stop Solution	Red Cap	1 x 15 mL		
20X Wash Solution	White Cap	1 x 50 mL	4°C for 6 Months	
Anti-Human IgG HRP Conjugate	Black Cap	1 x 20 mL		
TMB Substrate	Yellow Cap	1 x 15 mL		
Cytomegalovirus IgG Cut-Off Control	Green Cap	1 x 3 mL		
Cytomegalovirus IgG Positive Control	Red Cap	1 x 2 mL		
Cytomegalovirus IgG Negative Control	Blue Cap	1 x 2 mL		



5. Precautions

- Read instructions fully prior to beginning use of the assay kit.
- Any deviations or modifications from the described method or use of other reagents could result in a reduction of performance.
- Reduce exposure to potentially harmful substances by wearing personal protective lab equipment including lab coats, gloves and glasses.
- For information on hazardous substances included in the kit please refer to the Material Safety Data Sheet (MSDS).
- Kit cannot be used beyond the expiration date on the label.

6. Required Materials Not Supplied

- Microplate reader capable of reading absorbance at 450 nm.
- Automated plate washer (optional).
- Pipettes capable of precisely dispensing 0.5 µL through 1 mL volumes of aqueous solutions.
- Pipettes or volumetric glassware capable of precisely measuring 1 mL through 100 mL of aqueous solutions.
- New, clean tubes and/or micro-centrifuge tubes for the preparation of standards or samples.
- Absorbent paper or paper toweling.
- Distilled or deionized ultrapure water.
- 37°C Incubator (optional)

7. Technical Application Tips

- Do not mix or substitute components from other kits.
- To ensure the validity of experimental operation, it is recommended that pilot experiments using standards and a small selection of sample dilutions to ensure optimal dilution range for quantitation.
- Samples exhibiting OD measurements higher than the highest standard should be diluted further in the appropriate sample dilution buffers.
- Prior to using the kit, briefly spin component tubes to collect all reagents at the bottom.
- Replicate wells are recommended for standards and samples.
- Cover microplate while incubating to prevent evaporation.
- Do not allow the microplate wells dry at any point during the assay procedure.
- Do not reuse tips or tube to prevent cross contamination.
- Avoid causing bubbles or foaming when pipetting, mixing or reconstituting.
- Completely remove of all liquids when washing to prevent cross contamination.
- Prepare reagents immediately prior to use and do not store, with the exception of the top standard.
- Equilibrate all materials to ambient room temperature prior to use (standards exception).
- For optimal results for inter- and intra-assay consistency, equilibrate all materials to 37°C prior to performing assay (standards exception) and perform all incubations at 37°C.
- Pipetting less than 1 µL is not recommended for optimal assay accuracy.
- Once the procedure has been started, all steps should be completed without interruption. Ensure that all reagents, materials and devices are ready at the appropriate time.
- Incubation times will affect results. All wells should be handled in the same sequential order and time intervals for optimal results.
- Samples containing precipitates, fibrin strands or bilirubin, or are hemolytic or lipemic might cause inaccurate results due to interfering factors.
- TMB Substrate is easily contaminated and should be colorless or light blue until added to plate. Handle carefully and protect from light.



8. Reagent Preparation

- Equilibrate all materials to room temperature prior to use and use prepare immediately prior to use.
- The following reagents are provided at ready to use concentrations and require no preparation:
 - Sample Diluent
 - Stop Solution
 - Anti-Human IgG HRP Conjugate
 - TMB Substrate
 - Cytomegalovirus IgG Cut-Off Control
 - Cytomegalovirus IgG Positive Control
 - Cytomegalovirus IgG Negative Control

8.1 1X Wash Buffer

- 8.1.1 If crystals have formed in the 20X **Wash Buffer** concentrate, equilibrate to room temperature and mix gently until crystals have completely dissolved.
- 8.1.2 For 500 mL, add 25 mL contents of the 20X **Wash Buffer** bottle to 480 mL of ultra-pure water to a clean > 1,000 mL bottle or other vessel.
- 8.1.3 Seal and mix gently by inversion. Avoid foaming or bubbles.
- 8.1.4 Store the **1X Wash Buffer** at room temperature until ready to use in the procedure. Store the prepared **1X Wash Buffer** at 4°C for no longer than 1 week. Do not freeze.

8.2 Microplate Preparation

- Micro-plates are provided ready to use and do not require rinsing or blocking.
- Unused well strips should be returned to the original packaging, sealed and stored at 4°C.
- Equilibrate microplates to ambient temperatures prior to opening to reduce potential condensation.



9. Sample Preparation

9.1 Sample Preparation and Storage

- Store samples to be assayed at 2-8°C for 24 hours prior being assayed.
- For long term storage, aliquot and freeze samples at -20°C. Avoid repeated freeze-thaw cycles.
- Samples not indicated in the manual must be tested to determine if the kit is valid.
- Prepare samples as follows:
- Serum Use a serum separator tube (SST) and allow samples to clot for two hours at room temperature or overnight at 4°C before centrifugation for 15 minutes at 1,000 x g. Remove serum and assay immediately or aliquot and store samples at -20°C or -80°C. Avoid repeated freeze-thaw cycles.
- Plasma Collect plasma using EDTA, or heparin as an anticoagulant. Centrifuge for 15 minutes at 1,000 x g at 2-8°C within 30 minutes of collection. Assay immediately or aliquot and store samples at -20°C or -80°C. Avoid repeated freeze-thaw cycles.

9.2 Sample Dilution (1:100)

Target protein concentration must be estimated and appropriate sample dilution selected such that the final target protein concentration falls near the middle of the assay linear dynamic range. Samples exhibiting saturation should be further diluted.

- Dilute samples using Sample Diluent.
- Mix diluted samples gently and thoroughly.
- Pipetting less than 2 µL is not recommended for optimal assay accuracy.

The suggested 100-fold dilution can be achieved by adding 10 µL sample to 990 µL of **Sample Diluent**.



10. Assay Procedure

- Equilibrate all reagents and materials to ambient room temperature prior to use in the procedure.
- Optimal results for inter- and intra-assay reproducibility will be observed when incubation at 37°C as indicated in the procedure below.
- **10.1** Determine the required number of wells and return any remaining unused wells and desiccant to the pouch. Allow additional wells to include the following (recommended in duplicate):
 - 10.1.1 Substrate Blank
 - 10.1.2 Negative Control
 - 10.1.3 Cut-Off Control
 - 10.1.4 Positive Control
- 10.2 Add 100 μL of the 1:100 diluted samples, Positive Control, Cut-Off Control or Negative Control to test wells of the Cytomegalovirus IgG Microplate. At least two replicates are recommended.
- **10.3** Cover the plate with the well plate lid and incubate at 37±1°C for 60±5 minutes.
- **10.4** Remove the plate lid and discard the liquid in the wells by rigorously flicking into an acceptable waste receptacle or aspiration.
- **10.5** Gently blot any remaining liquid from the wells by tapping inverted on the benchtop onto paper toweling. Do not allow the wells to completely dry at any time.
- 10.6 Wash plate 3 times with 1X Wash Buffer as follows:
 - 10.6.1 Add 300 µL of **1X Wash Buffer** to each assay well.
 - 10.6.2 Allow to soak for ~ 5 seconds.
 - 10.6.3 Discard the liquid in the wells by rigorously flicking into an acceptable waste receptacle.
 - 10.6.4 Gently blot any remaining liquid from the wells by tapping inverted on the benchtop onto paper toweling. Do not allow the wells to completely dry at any time.
 - 10.6.5 Repeat steps 10.6.1 through 10.6.4 **two** more times.
- 10.7 Add 100 µL of the 1X Anti-Human IgG HRP-Conjugate to all the wells.
- **10.8** Cover with the well-plate lid and incubate at room temperature for 30 minutes.
- **10.9** Remove the plate lid and discard the liquid in the wells by rigorously flicking into an acceptable waste receptacle or aspiration.
- **10.10** Gently blot any remaining liquid from the wells by tapping inverted on the benchtop onto paper toweling. Do not allow the wells to completely dry at any time.
- **10.11** Repeat the wash in step 10.6.
- **10.13** Add 100 μL of **TMB Substrate** to each well and incubate at room temperature **in the dark** for 15 minutes.
- 10.14 Add 100 µL of Stop Solution to each well in the same order as that of step 10.13.
- **10.15** Read the O.D. absorbance at 450 nm with a standard microplate reader within 30 minutes of stopping the reaction in step 10.14. If wavelength correction is available, set to 620 nm.



11. Calculation of Results

A positive or negative Cytomegalovirus IgG determination is derived by comparing the test samples to the **Positive** and **Negative Controls**.

11.1 Calculation of Results

- The **Cut-Off** is the mean 450 nm absorbance (A₄₅₀) value of the **Cut-Off Control** sample determinations.
- The Test Specimen measurement is the mean of the replicate A₄₅₀ measurements.

11.2 Run Validation Criteria

For an assay to be considered valid, the following criteria must be met:

Substrate blank: Absorbance value < 0.100.

Cytomegalovirus IgG Negative control: Absorbance value < 0.200 and < Cut-Off

Cytomegalovirus IgG Cut-off Control: Absorbance value 0.150 – 1.30 Cytomegalovirus IgG Positive control: Absorbance value > Cut-Off If these criteria are not met, the test is not valid and must be repeated.

11.3 Interpretation of Results

The criteria to establish the results of an assay run using mean absorbance values are as follows:

Test samples are considered POSITIVE if the absorbance value is higher than 10% over the Cut-Off.

Samples with an absorbance value of <10% above or below the Cut-Off should not be considered as clearly positive or negative (grey zone). It is recommended to repeat the test again 2 - 4 weeks later with a fresh sample. If results in the second test are again in the grey zone the sample must be considered NEGATIVE.

Samples are considered NEGATIVE if the absorbance value is lower than 10% below the Cut-Off.



12 Typical Expected Data

12.1 Precision

Replicate samples were measured to assess inter- and intra-assay reproducibility.

Metric	Sample Type	n=	Mean	CV%
Inter-Assay	Positive Serum	4	77.2	6.2
Intra-Assay	Positive Serum	12	2.86	1.9

12.2 Specificity

Specificity is determined as the probability of the assay indicating a negative score in samples absent of the specific analyte: >97.5%

12.3 Sensitivity

Sensitivity is determined as the probability of the assay indicating a positive score in samples with the specific analyte present: >98%

12.4 Interference Factors

Interferences with hemolytic, lipemic or icteric sera are not observed up to a concentration of 10 mg/ml hemoglobin, 5 mg/ml triglycerides and 0.2 mg/ml bilirubin.



13 Technical Resources

Technical Support:

For optimal service please be prepared to supply the lot number of the kit used.

<u>USA</u>

Aviva Systems Biology, Corp. 5754 Pacific Center Blvd, Suite 201 San Diego, CA 92121

Phone: 858-552-6979 Toll Free: 888-880-0001 Fax: 858-552-6975

Technical support: techsupport@avivasysbio.com

China

Beijing AVIVA Systems Biology 6th Floor, B Building, Kaichi Tower #A-2 Jinfu Road. Daxing Industrial Development Zone Beijing, 102600, CHINA

Phone: (86)10-60214720 Fax: (86)10-60214722

E-mail: support@avivasysbio.com.cn

中国地址:北京大兴工业开发区金辅路甲 2 号凯驰大厦 B 座 6 层 (102600)

电话: 010-60214720/21 传真: 010-60214722

产品售前咨询及销售: sales@avivasysbio.com.cn售后及技术支持: support@avivasysbio.com.cn